NCT03842228: Copanlisib, Olaparib, and Durvalumab in Treating Patients With Metastatic or Unresectable Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ATM, ATR, ARID1A, DNA damage repair mutations, BRCA+, CDK, POLD, PTEN, PI3K
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known, active, unstable, or untreated central nervous system (CNS) metastases and/or leptomeningeal disease – see trial for details

Comments are closed.

Up ↑